These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 9736556

  • 1. Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases.
    Sabbagh Y, Thériault E, Sanschagrin F, Voyer N, Palzkill T, Levesque RC.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2319-25. PubMed ID: 9736556
    [Abstract] [Full Text] [Related]

  • 2. Structure-function analysis of alpha-helix H4 using PSE-4 as a model enzyme representative of class A beta-lactamases.
    Savoie A, Sanschagrin F, Palzkill T, Voyer N, Levesque RC.
    Protein Eng; 2000 Apr; 13(4):267-74. PubMed ID: 10810158
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C, Kotra LP, Sanschagrin F, Mobashery S, Levesque RC.
    FEBS Lett; 2000 Mar 31; 470(3):285-92. PubMed ID: 10745083
    [Abstract] [Full Text] [Related]

  • 4. Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
    Ohsuka S, Arakawa Y, Horii T, Ito H, Ohta M.
    Antimicrob Agents Chemother; 1995 Aug 31; 39(8):1856-8. PubMed ID: 7486932
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P, Tzelepi E, Legakis NJ, Tzouvelekis LS.
    J Antimicrob Chemother; 1999 Jan 31; 43(1):23-9. PubMed ID: 10381097
    [Abstract] [Full Text] [Related]

  • 7. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
    Payne DJ, Cramp R, Winstanley DJ, Knowles DJ.
    Antimicrob Agents Chemother; 1994 Apr 31; 38(4):767-72. PubMed ID: 8031044
    [Abstract] [Full Text] [Related]

  • 8. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX, McElrath MJ, Neu HC.
    Chemotherapy; 1988 Apr 31; 34(4):318-25. PubMed ID: 2850139
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
    Blazquez J, Baquero MR, Canton R, Alos I, Baquero F.
    Antimicrob Agents Chemother; 1993 Oct 31; 37(10):2059-63. PubMed ID: 8257123
    [Abstract] [Full Text] [Related]

  • 11. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G, Mascaretti O, Radice M, Power P, Calcagno ML, Mata EG, Gutkind G.
    J Antimicrob Chemother; 1998 Feb 31; 41(2):313-5. PubMed ID: 9533481
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
    Kalp M, Totir MA, Buynak JD, Carey PR.
    J Am Chem Soc; 2009 Feb 18; 131(6):2338-47. PubMed ID: 19161282
    [Abstract] [Full Text] [Related]

  • 14. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
    Bethel CR, Taracila M, Shyr T, Thomson JM, Distler AM, Hujer KM, Hujer AM, Endimiani A, Papp-Wallace K, Bonnet R, Bonomo RA.
    Antimicrob Agents Chemother; 2011 Jul 18; 55(7):3465-75. PubMed ID: 21555770
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S, Marre R.
    Infection; 1991 Jul 18; 19(2):106-9. PubMed ID: 1646771
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
    Papp-Wallace KM, Taracila M, Hornick JM, Hujer AM, Hujer KM, Distler AM, Endimiani A, Bonomo RA.
    Antimicrob Agents Chemother; 2010 Jul 18; 54(7):2867-77. PubMed ID: 20421396
    [Abstract] [Full Text] [Related]

  • 20. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
    Totir MA, Cha J, Ishiwata A, Wang B, Sheri A, Anderson VE, Buynak J, Mobashery S, Carey PR.
    Biochemistry; 2008 Apr 01; 47(13):4094-101. PubMed ID: 18324783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.